139 related articles for article (PubMed ID: 16240400)
1. Malignant effusions are sources of fibronectin and other promigratory and proinvasive components.
Kohn EC; Travers LA; Kassis J; Broome U; Klominek J
Diagn Cytopathol; 2005 Nov; 33(5):300-8. PubMed ID: 16240400
[TBL] [Abstract][Full Text] [Related]
2. Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma: evidence of up-regulated Tn and Sialyl Tn antigen expression in effusions.
Davidson B; Berner A; Nesland JM; Risberg B; Kristensen GB; Tropé CG; Bryne M
Hum Pathol; 2000 Sep; 31(9):1081-7. PubMed ID: 11014575
[TBL] [Abstract][Full Text] [Related]
3. Proinvasive properties of ovarian cancer ascites-derived membrane vesicles.
Graves LE; Ariztia EV; Navari JR; Matzel HJ; Stack MS; Fishman DA
Cancer Res; 2004 Oct; 64(19):7045-9. PubMed ID: 15466198
[TBL] [Abstract][Full Text] [Related]
4. Proteomic analysis of malignant ovarian cancer effusions as a tool for biologic and prognostic profiling.
Davidson B; Espina V; Steinberg SM; Flørenes VA; Liotta LA; Kristensen GB; Tropé CG; Berner A; Kohn EC
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):791-9. PubMed ID: 16467090
[TBL] [Abstract][Full Text] [Related]
5. Gelatinolytic activities (matrix metalloproteinase-2 and -9) and soluble extracellular domain of Her-2/neu in pleural effusions.
Di Carlo A; Mariano A; Terracciano D; Mazzarella C; Galzerano S; Cicalese M; Cecere C; Macchia V
Oncol Rep; 2007 Aug; 18(2):425-31. PubMed ID: 17611666
[TBL] [Abstract][Full Text] [Related]
6. Ovarian carcinoma cells in serous effusions show altered MMP-2 and TIMP-2 mRNA levels.
Davidson B; Reich R; Berner A; Givant-Horwitz V; Goldberg I; Risberg B; Kristensen GB; Trope CG; Bryne M; Kopolovic J; Nesland JM
Eur J Cancer; 2001 Nov; 37(16):2040-9. PubMed ID: 11597382
[TBL] [Abstract][Full Text] [Related]
7. Ovarian carcinoma cells and IL-1beta-activated human peritoneal mesothelial cells are possible sources of vascular endothelial growth factor in inflammatory and malignant peritoneal effusions.
Stadlmann S; Amberger A; Pollheimer J; Gastl G; Offner FA; Margreiter R; Zeimet AG
Gynecol Oncol; 2005 Jun; 97(3):784-9. PubMed ID: 15943987
[TBL] [Abstract][Full Text] [Related]
8. Positive effusion cytology as the initial presentation of malignancy.
Monte SA; Ehya H; Lang WR
Acta Cytol; 1987; 31(4):448-52. PubMed ID: 3604540
[TBL] [Abstract][Full Text] [Related]
9. The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma.
Gorovetz M; Baekelandt M; Berner A; Trope' CG; Davidson B; Reich R
Gynecol Oncol; 2006 Dec; 103(3):831-40. PubMed ID: 16919315
[TBL] [Abstract][Full Text] [Related]
10. D2-40 is not a specific marker for cells of mesothelial origin in serous effusions.
Bassarova AV; Nesland JM; Davidson B
Am J Surg Pathol; 2006 Jul; 30(7):878-82. PubMed ID: 16819331
[TBL] [Abstract][Full Text] [Related]
11. Molecular prognostic markers in recurrent and in non-recurrent epithelial ovarian cancer.
Demeter A; Sziller I; Csapo Z; Olah J; Keszler G; Jeney A; Papp Z; Staub M
Anticancer Res; 2005; 25(4):2885-9. PubMed ID: 16080542
[TBL] [Abstract][Full Text] [Related]
12. Kallikrein 4 expression is up-regulated in epithelial ovarian carcinoma cells in effusions.
Davidson B; Xi Z; Klokk TI; Tropé CG; Dørum A; Scheistrøen M; Saatcioglu F
Am J Clin Pathol; 2005 Mar; 123(3):360-8. PubMed ID: 15716231
[TBL] [Abstract][Full Text] [Related]
13. Differential expression of the 67 kilodalton laminin receptor in epithelioid malignant mesothelioma and carcinomas that spread to serosal cavities.
Reich R; Vintman L; Nielsen S; Kaern J; Bedrossian C; Berner A; Davidson B
Diagn Cytopathol; 2005 Nov; 33(5):332-7. PubMed ID: 16240397
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory effects of a benz[f]indole-4,9-dione analog on cancer cell metastasis mediated by the down-regulation of matrix metalloproteinase expression in human HT1080 fibrosarcoma cells.
Park HJ; Lee HJ; Min HY; Chung HJ; Suh ME; Park-Choo HY; Kim C; Kim HJ; Seo EK; Lee SK
Eur J Pharmacol; 2005 Dec; 527(1-3):31-6. PubMed ID: 16309669
[TBL] [Abstract][Full Text] [Related]
15. [Matrix metalloproteinases and their inhibitors in lung cancer with malignant pleural effusion].
Moche M; Hui DS; Huse K; Chan KS; Choy DK; Scholz GH; Gosse H; Winkler J; Schauer J; Sack U; Hoheisel G
Pneumologie; 2005 Aug; 59(8):523-8. PubMed ID: 16110415
[TBL] [Abstract][Full Text] [Related]
16. Activated coagulation factors in human malignant effusions and their contribution to cancer cell metastasis and therapy.
Gieseler F; Lühr I; Kunze T; Mundhenke C; Maass N; Erhart T; Denker M; Beckmann D; Tiemann M; Schulte C; Dohrmann P; Cavaillé F; Godeau F; Gespach C
Thromb Haemost; 2007 Jun; 97(6):1023-30. PubMed ID: 17549306
[TBL] [Abstract][Full Text] [Related]
17. Tumor microenvironment: what can effusions teach us?
Kassis J; Klominek J; Kohn EC
Diagn Cytopathol; 2005 Nov; 33(5):316-9. PubMed ID: 16240401
[TBL] [Abstract][Full Text] [Related]
18. Correlation of cytologic examination with ELISA assays for hyaluronan and soluble CD44v6 levels in evaluation of effusions.
Afify A; Lynne LC; Howell L
Diagn Cytopathol; 2007 Feb; 35(2):105-10. PubMed ID: 17230576
[TBL] [Abstract][Full Text] [Related]
19. MUC4 is upregulated in ovarian carcinoma effusions and differentiates carcinoma cells from mesothelial cells.
Davidson B; Baekelandt M; Shih IeM
Diagn Cytopathol; 2007 Dec; 35(12):756-60. PubMed ID: 18008338
[TBL] [Abstract][Full Text] [Related]
20. Tissue inhibitor of metalloproteinase 2 (TIMP-2) expression in adenocarcinoma pleural effusions.
Giarnieri E; Alderisio M; Mancini R; Falasca C; Ricci A; Mariotta S; Giovagnoli MR
Oncol Rep; 2008 Feb; 19(2):483-7. PubMed ID: 18202798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
